CSL acquires option to Pevion's candidiasis vaccine
This article was originally published in Scrip
Executive Summary
In the first deal for the product, CSL has acquired the right of first refusal to a licence to commercialise Pevion Biotech's therapeutic vaccine against Candida albicans, PEV7, in Australia and New Zealand.